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Revised The errors in the Results section, should read as:
A total of 1096 patients with various types of cancers were from People's Republic of China, Japan, Spain and Brazil. Quantitative real-time PCR (qRT-PCR) was used to assess the expression of miR-17 in all studies.
Open access
and was incorrectly published as:
A total of 1096 patients with various types of cancers were from People's Republic of China, Japan, Spain and Brazil. Quantitative real-time PCR (qRT-PCR) was used to assess the expression of miR-17 in 12 studies, and one study used the in situ hybridisation (ISH).
The errors in the Discussion section, should read as:
In the subgroup analysis, we found that the potential heterogeneity may have originated from the non-Asian group studies.
In the subgroup analysis, we found that the potential heterogeneity may have originated from the Caucasian group in the study conducted by Robaina et al. Unlike the commonly used RT-PCR, ISH technique was used to detect miR-17
However, both studies from Spain and Brazil recruited population of non-Asians decreasing the heterogeneity.
However, both studies from Spain and Brazil recruited population of Caucasians decreasing the heterogeneity.
In subgroup analysis, based on the characteristics of the individual studies, significant HR was found in the non-Asian and Asian groups, and the tissue and serum sample groups.
In subgroup analysis, based on the characteristics of the individual studies, significant HR was found in the Caucasian and Asian groups, the qRT-PCR group and the tissue and serum sample groups.
The errors in the Conclusion section, should read as:
However, further multicentre clinical trials with larger sample size and prospective studies including non-Asian and patients representing other ethnicities are needed to confirm the prognostic value of miR-17 and its subsequent application as a prognostic biomarker in the routine clinical guidance of cancers.
However, further multicentre clinical trials with larger sample size and prospective studies including Caucasians and patients representing other ethnicities are needed to confirm the prognostic value of miR-17 and its subsequent application as a prognostic biomarker in the routine clinical guidance of cancers.
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